For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Abaloparatide
Illustration for Abaloparatide

THE PEPSRADAR ENCYCLOPEDIA

Abaloparatide

Bone formation in osteoporosis care

Prescription medicines · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

Abaloparatide · KEY FACTS

Content updated · how dates work

Saved peptides

Half-life source: FDA label (Tymlos) on DailyMed ↗

What is Abaloparatide?

Abaloparatide is a bone-forming prescription medicine for osteoporosis. Its clinically relevant outcome is prevention of fractures in appropriately selected patients.

Biological role or research focus

Bone formation in osteoporosis care.

Its clinical context is selected patients at high fracture risk, not general joint repair.

Role reference: MedlinePlus · Abaloparatide ↗

Names you may encounter

Tymlos

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
PTH1 receptor agonist
Main research area
Bone formation
Evidence featured
Human randomized trial
Source check
October 4, 2026

Source: MedlinePlus · Abaloparatide ↗

Quick answers

Is Abaloparatide FDA approved?
Yes. Tymlos (NDA 208743, approved 2017) for osteoporosis in people at high risk of fracture. Source ↗
Is Abaloparatide safe?
Approved bone-building drug for osteoporosis; the main label concerns are bone cancer seen in rats, dizziness from a drop in blood pressure, and high calcium levels. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
Is Abaloparatide banned in sport?
It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

2 Human research
StudyTypePopulation / model
ACTIVE (2016)Human randomized trial2,463 postmenopausal women with osteoporosis.
ACTIVExtend · sequential treatment (2018)Human trial extension558 prior abaloparatide recipients and 581 prior placebo recipients who completed ACTIVE.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human randomized trial · 2016

ACTIVE

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.

Population / model
2,463 postmenopausal women with osteoporosis.
Study design
18 months; blinded abaloparatide versus placebo, with an open-label teriparatide arm.
Main finding
New vertebral and nonvertebral fractures were less frequent with abaloparatide than placebo, and bone mineral density increased. Hypercalcemia occurred in 3.4% with abaloparatide versus 6.4% with teriparatide.
Limits & context
The trial addresses fracture prevention in osteoporosis. The open-label comparator and selected population limit claims of universal superiority or benefit for healthy athletes.

Source: Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. ↗

Human trial extension · 2018

ACTIVExtend · sequential treatment

Were fracture benefits maintained after switching to another medicine?

Population / model
558 prior abaloparatide recipients and 581 prior placebo recipients who completed ACTIVE.
Study design
Both groups received alendronate for up to 24 months; outcomes were measured across the original trial and extension.
Main finding
Across 43 months, new radiographic vertebral fractures occurred in 0.9% versus 5.6% of evaluable women, favoring the abaloparatide-to-alendronate sequence.
How to read it
The absolute difference was 4.7 percentage points. The reported 84% relative reduction is a different measure.
Limits & context
Completer selection and sequential alendronate treatment limit attribution. This is not evidence for uninterrupted abaloparatide, general bone repair, or outcomes in healthy people.

Source: ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

23 registered studies name Abaloparatide as an intervention; 5 are recruiting or under way, 2 have not started recruiting yet, 13 completed and 3 ended early, were withdrawn or have another status. Checked November 14, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
NCT04467983 · Hospital for Special Surgery, New York
Active, not recruitingPhase 42021-02-0170
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
NCT03841058 · Hospital for Special Surgery, New York
Active, not recruitingPhase 22019-08-1496
The Effect of Osteoporotic Medications on Vertebral Bone Quality Score
NCT07587775 · State University of New York at Buffalo
Enrolling by invitationPhase 22026-06-1860
Sequential Therapies After Osteoanabolic Treatment
NCT06164795 · 424 General Military Hospital
Recruiting2023-11-25150
Abaloparatide Before Total Knee Arthroplasty
NCT04167163 · University of Wisconsin, Madison
CompletedPhase 42020-01-1058
MicroRNA and Markers and Therapeutic Response to Romosozumab and Abaloparatide in Postmenopausal Osteoporosis
NCT07616401 · Istituto Auxologico Italiano
RecruitingNot applicable2025-08-3142
To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture
NCT06898060 · Qilu Pharmaceutical Co., Ltd.
Not yet recruitingPhase 32025-06282
A Single-center, Open, Randomized, Single-dose, Cross-over Bioequivalence Study to Evaluate the Effects of the Test Formulation Abalparatide Injection and the Reference Formulation Abalparatide Injection (Tymlos®) in Healthy Adult Subjects
NCT06753864 · The Affiliated Hospital of Qingdao University
Not yet recruitingPhase 12025-01-0232

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 23 listed studies.

Further reading · 3 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

Osteoporosis: A Review. ↗
JAMA · 2025 Sep 9 · Journal Article, Review

The 2024 UK clinical guideline for the prevention and treatment of osteoporosis. ↗
Archives of osteoporosis · 2025 Sep 8 · Journal Article, Practice Guideline
Read available full text ↗

Recent Advances in Osteoporosis Therapeutics. ↗
Annual review of medicine · 2026 Jan · Journal Article, Review

Repeat this PubMed search ↗
Search additional PubMed records ↗

Risks & interactions

Approved bone-building drug for osteoporosis; the main label concerns are bone cancer seen in rats, dizziness from a drop in blood pressure, and high calcium levels.

Human safety data: FDA label

Safety comes from FDA-approved labeling (Tymlos) based on a large placebo-controlled trial in postmenopausal women and a trial in men with osteoporosis. The label notes limited data on bone cancer risk with longer-term use of this drug class, and no formal drug interaction studies.

Take extra care with: Heart or blood pressure problemsCancer, now or in the pastKidney problems

From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.

Who should not use it

  • People with a past severe allergic reaction to abaloparatide or any ingredient
  • Label advises avoiding use in people at higher risk of bone cancer (osteosarcoma), such as those with Paget's disease, bone metastases, prior skeletal radiation or open growth plates
  • Not recommended with high blood calcium or a condition that raises it, such as primary hyperparathyroidism

Serious risks

  • Severe allergic reactions, including anaphylaxis and angioedema
  • Osteosarcoma (bone cancer) in rats; unknown whether it occurs in humans
  • Drop in blood pressure on standing, with dizziness, fast heartbeat or nausea
  • High blood calcium
  • High urine calcium; unknown whether it worsens kidney stones

Common side effects

  • high urine calcium
  • dizziness
  • nausea
  • headache
  • palpitations
  • fatigue
  • upper abdominal pain
  • injection-site reactions

Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Tymlos (abaloparatide) prescribing information ↗

Key precautions

Dizziness, nausea, palpitations, and increased calcium are relevant concerns. Kidney stones and conditions associated with greater osteosarcoma risk require clinical review; the animal tumor finding should not be described as proven human causation.

Source: MedlinePlus · Abaloparatide ↗

Regulatory status

U.S. FDA approval
Approved
Tymlos (NDA 208743, approved 2017) for osteoporosis in people at high risk of fracture. source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source
World Anti-Doping Agency (2026)
Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Clinical uses & product context

The medication reference describes osteoporosis care. Treatment selection depends on fracture risk, previous therapies, and the exact product label. A bone-density change is useful, but fracture outcomes provide the more direct clinical test.

Source: MedlinePlus · Abaloparatide ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Why there are no prices here

This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.

Mechanism & research rationale

It activates the parathyroid-hormone type 1 receptor. The therapeutic aim is increased bone formation and strength; this is a different biological question from repairing tendons or cartilage.

Source: MedlinePlus · Abaloparatide ↗

Molecular structure

Abaloparatide: 2d molecular structure. The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.⤢ Enlarge 2D
2D molecular structureThe cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.PubChem · CID 76943386 ↗

Questions worth asking

  • Which indication and formulation does the source describe?
  • Does the video make a broader claim than the source supports?
  • Its clinical context is selected patients at high fracture risk, not general joint repair.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Frequently asked questions

Is stronger bone the same as joint repair?

No. Osteoporosis trials measure bone density and fractures. Those findings do not establish cartilage regeneration or tendon recovery.

Source: MedlinePlus · Abaloparatide ↗

Was it proven better than every alternative?

No. ACTIVE included an open-label teriparatide arm, but it does not provide a universal ranking across osteoporosis treatments.

Source: Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

Abaloparatide

Download illustration ↓Source record ↗
Abaloparatide 2d molecular structure

The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.